“We are delighted to enter into this collaboration with Gustave Roussy, a leading comprehensive cancer center in Europe and worldwide,” said Corinne Danan, general manager of Veracyte’s Biopharma business unit. “This partnership will enable us to augment our Veracyte Biopharma Atlas reference database with a large number of patients tumor samples and data from innovative cancer therapies. Ultimately, we believe this tool may help our biopharmaceutical partners accelerate development of new, precision-medicine therapies that improve outcomes for patients with cancer.”

Applied Cells is excited to invite researchers from around the globe to submit proposals that align with four distinct research areas.

Carisma notes the presentation includes data from group 1 (n=9) and group 2 (n=5). Patients in both groups received the same total dose (up to 5×109 CT-0508) either via a fractionated, multi-day infusion regimen (group 1) or via a single-day bolus infusion (group 2).

Umami Bioworks and Maruha Nichiro will be working to build the infrastructure of Japan’s cultivated seafood industry together in this partnership. The strategic investment from Maruha Nichiro will help accelerate Umami’s development progress.

In 2023, CAR T cell therapy can cost between $500,000 and $1,000,000. Being one of the most expensive Medicare diagnosis-related drugs, the collection and manufacturing of T cells plays a large role in this excessive cost. Akadeum Life Sciences microbubble technology provides a more economical, cost-effective solution that is faster, and more adept at maintaining cell physiology.